株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオインフォマティクス:各種技術と世界の市場

Bioinformatics: Technologies and Global Markets

発行 BCC Research 商品コード 268909
出版日 ページ情報 英文 158 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
バイオインフォマティクス:各種技術と世界の市場 Bioinformatics: Technologies and Global Markets
出版日: 2016年01月29日 ページ情報: 英文 158 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のバイオインフォマティクスの市場は2013年に36億ドル、2014年には41億ドルの規模を記録しました。2014年から2019年にかけては14.2%のCAGRで推移し、2015年の47億ドルから、2019年には80億ドルの規模に成長すると予測されています

当レポートでは、世界のバイオインフォマティクス市場について調査し、バイオインフォマティクスの定義と目標、膨大な生物学的データとその用途、データの生成・管理・解析・処理とコンピューティング技術、各種オミクス研究におけるデータ利用、医薬品の研究開発におけるバイオインフォマティクスの利用、カテゴリー・用途・地域別の市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 ビッグデータとバイオインフォマティクス

  • バイオインフォマティクスの目標
  • 生物学的データソース
    • システム生物学におけるバイオインフォマティクス
    • PRECISION MEDICINE (精密医療)
    • 薬剤開発におけるバイオインフォマティクス
    • ケモインフォマティクス
    • 次世代シーケンシング
    • メタゲノミクス
    • データ管理システム
  • 市場動向
    • PRECISION MEDICINE (精密医療) とバイオマーカーの同定
    • クラウドベースのソリューション
    • 価値ベースのケアへの移行
  • 市場課題
    • データ統合
    • データの信頼性・標準化
    • エンドツーエンドのワークフロー
  • 現在の市場
  • 地域別市場
  • カテゴリー別市場
    • 公的資金
    • 民間資金
  • 用途別市場

第4章 バイオインフォマティクス:データ生成とデータ管理

  • 情報オーバーロード
    • データ量
    • データの多様性
    • データの速度
    • データの正確度
  • ビッグデータ世代の技術
  • ゲノミクスの進化
    • シーケンシングゲノミクス
    • 機能ゲノミクス
  • プロテオミクスの進化
    • 定量的プロテオミクス
    • 定性的プロテオミクス
    • 構造プロテオミクス
    • 相互作用プロテオミクス
    • トランスクリプトームの進化
  • メタボロミクスの進化
  • ケモインフォマティクスの進化
  • 新興技術
    • メタゲノミクスの進化
  • エピゲノミクス の進化
  • 薬理ゲノミクスの進化
    • 薬理ゲノミクスとPRECISION MEDICINE (精密医療)
    • 価値ベースの意思決定
    • 薬理ゲノミクスとR&D
    • iSAEC (INTERNATIONAL SERIOUS ADVERSE EVENTS CONSORTIUM)
    • 薬理ゲノミクスソフトウェア
  • トキシコゲノミクスの進化
    • TOXCASTプログラム
    • カスタマイズドトキシコゲノミクスプラットフォーム
  • データベース管理サービス
  • 市場力学

第5章 バイオインフォマティクス:データアナリティクスとソフトウェア

  • イントロダクション
  • データアナリティクスソフトウェア
  • バイオシミュレーションモデル
  • 市場分析

第6章 バイオインフォマティクス:データ処理とストレージ

  • ギャップへの配慮
  • 情報技術インフラ
  • 高性能コンピューティング
  • 高性能コンピュータークラスター
    • クラウドコンピューティング
    • DaaS (DATA AS A SERVICE)
    • IaaS (INFRASTRUCTURE AS A SERVICE)
    • PaaS (PLATFORM AS A SERVICE)
    • SaaS (SOFTWARE AS A SERVICE)
    • SaaS (SECURITY AS A SERVICE)
    • クラウドコンピューティングの課題
    • クラウドコンピューティングの将来
  • 市場分析

第7章 医薬品R&Dへのバイオインフォマティクスの導入

  • イントロダクション
  • 創薬・薬剤開発プロセス
  • 前臨床研究:創薬フェーズ
    • 標的同定
    • 標的バリデーション
    • リード化合物の同定
    • コンピューター支援による薬剤設計
    • リードの最適化
    • 臨床研究:薬剤開発
    • 前臨床実験
    • ラボ情報管理システム
    • 電子ラボノート
    • 新薬申請のための調査
    • 臨床試験
    • 臨床試験設計・データ照合におけるバイオインフォマティクス
    • 新薬の申請
    • 新薬の承認
    • 上市後の継続的研究・第IV相臨床試験
    • EHR (電子医療記録)
    • モバイルヘルス技術
    • 近年の医薬品・バイオインフォマティクス事業者の提携・アライアンスなど
    • 総論

第8章 市場動向・分析

  • 北米
  • 米国
  • カナダ
  • 欧州
  • 英国
  • ドイツ
  • スイス
  • アジア太平洋
  • インド
  • 中国
  • 総論

第9章 企業プロファイル

  • 3RD MILLENNIUM INC.
  • ASTRID BIOSCIENCE GMBH
  • BIOBASE GMBH
  • BIOMATTERS LTD.
  • CLC BIOINFORMATICS
  • CONEXIO GENOMICS PRIVATE LTD.
  • COMPUGEN LTD.
  • DASSAULT SYSTEMES SA
  • DNASTAR INC.
  • GEOSPIZA INC.
  • GENOMATIX SOFTWARE GMBH
  • GVK BIOSCIENCES PRIVATE LTD.
  • GENOLOGICS LIFESCIENCES SOFTWARE INC.
  • GENEDATA AG
  • GENEVA BIOFORMATICS (GENEBIO) SA
  • GNS HEALTHCARE INC.
  • ILLUMINA INC.
  • MOLECULAR CONNECTIONS PRIVATE LTD.
  • MOLECULAR NETWORKS GMBH
  • NONLINEAR DYNAMICS LTD.
  • OCIMUM BIOSOLUTIONS LTD.
  • PERKIN ELMER INFORMATICS INC.
  • PERSONALIS INC.
  • SMARTGENE SERVICES SARL
  • REAL TIME GENOMICS INC.

第10章 用語

第11章 参考資料

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO051C

REPORT HIGHLIGHTS

The global bioinformatic market was $3.6 billion and $4.1 billion in 2013 and 2014, respectively. This market is expected to reach $8.0 billion in 2019 from $4.7 billion in 2015 at a compound annual growth rate of 14.2% for the period 2014-2019.

The report provides:

  • An overview of the global market for bioinformatics based on geography, category and application.
  • Analyses of global market trends, with data from 2013 and 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2019.
  • Technological descriptions and patenting trends in bioinformatics.
  • Analysis of the market's dynamics, including opportunities, drivers, and restraints.
  • Examination of the economic environment effecting the deployment of bioinformatics.
  • Discussion of other influential factors, such as R&D spending in the pharmaceutical sector, the growth of agrobiotechnology, and the expanded use of microbial genomics.
  • Comprehensive company profiles of major players in the industry.

SCOPE OF REPORT

The scope of the study encompasses the global bioinformatic market based on geography, category and application. It provides a detailed analysis of recent advances in ‘omic technologies and examines their impact on the bioinformatic market. It discusses the ways in which bioinformatics has been utilized by the pharma and biotech industry to streamline the research and development (R&D) process and improve efficiencies. It provides a detailed analysis of leading countries, companies and technologies that will drive the field forward.

ANALYST'S CREDENTIALS

Dr. C.L. Barton has more than 10 years' practical pharmaceutical research experience with a leading pharmaceutical company and is a Pan-European pharmaceutical analyst with a European Bank.

Dr. C.L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Where applicable, the research reports combine independent scientific analysis with patient- and prescription-based models to forecast the potential sales growth of key developmental drugs and isolate the key drivers within the pharmaceutical sector.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL BIOINFORMATIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL BIOINFORMATIC MARKET BY REGION, 2013-2019 ($ MILLIONS)

CHAPTER 3 - BIG DATA: WHAT TO DO WITH IT?

  • GOAL OF BIOINFORMATICS
    • FIGURE 1 RELATIONSHIP OF BIOINFORMATICS WITH 'OMIC TECHNOLOGIES
  • BIOLOGICAL DATA SOURCES
    • BIOINFORMATICS IN SYSTEMS BIOLOGY
      • FIGURE 2 SCHEMATIC REPRESENTATION OF BIOLOGY SYSTEMS AND TRANSLATIONAL BIOINFORMATICS
    • PRECISION MEDICINE
      • FIGURE 3 PRINCIPLES OF PRECISION MEDICINE
    • BIOINFORMATICS IN DRUG DEVELOPMENT
      • FIGURE 4 APPLICATIONS OF BIOINFORMATICS ON DRUG DEVELOPMENT
    • CHEMINFORMATICS
    • NEXT-GENERATION SEQUENCING
    • METAGENOMICS
    • DATA MANAGEMENT SYSTEMS
  • MARKET TRENDS
    • TABLE 1: U.S. FOOD AND DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVALS, 2009-2014
    • PRECISION MEDICINE AND BIOMARKER IDENTIFICATION
    • CLOUD-BASED SOLUTIONS
    • SHIFT TOWARD VALUE-BASED CARE
  • MARKET CHALLENGES
    • DATA INTEGRATION
    • DATA RELIABILITY AND STANDARDIZATION
    • END-TO-END WORKFLOWS
  • CURRENT MARKET
  • MARKET BY REGION
    • TABLE 2: GLOBAL BIOINFORMATIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • MARKET BY CATEGORY
    • PUBLIC FUNDING
      • TABLE 3: PUBLIC FUNDING PROGRAMS, 2005-2014
    • PRIVATE FUNDING
      • TABLE 4: GLOBAL BIOINFORMATIC MARKET BY CATEGORY, THROUGH 2019 ($ MILLIONS)
  • MARKET BY APPLICATION
    • TABLE 5: GLOBAL BIOINFORMATIC MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)

CHAPTER 4 - BIOINFORMATICS: DATA GENERATION AND DATA MANAGEMENT

  • INFORMATION OVERLOAD
    • FIGURE 5: FOUR DIMENSIONS OF BIG DATA
    • DATA VOLUME
    • DATA VARIETY
    • DATA VELOCITY
    • DATA VERACITY
  • TECHNOLOGIES BEHIND BIG DATA GENERATION
  • GENOMIC ADVANCES
    • SEQUENCING GENOMICS
      • Metagenomics
      • Exponential Growth in Next-Generation Sequencing Software Tools
    • FUNCTIONAL GENOMICS
      • Functional Genomics in Drug Discovery
      • CRISPR Cas9 System
  • PROTEOMIC ADVANCES
    • QUALITATIVE PROTEOMICS
    • QUANTITATIVE PROTEOMICS
    • STRUCTURAL PROTEOMICS
      • Protein Structure Initiative
      • Structural Genomic Consortium
    • INTERACTION PROTEOMICS
      • Application in Drug Discovery
      • Bottom-Up versus Top-Down Proteomics
        • FIGURE 6: TOP-DOWN PROTEOMIC APPROACH
      • Emergence of Glycomics
      • Human Proteome Organization and the Human Proteome Project Initiative
    • TRANSCRIPTOMIC ADVANCES
      • RNA Sequencing
      • Co-Expression and Single-Cell RNA-Seq
  • METABOLOMIC ADVANCES
    • TABLE 6: COMMERCIALLY AVAILABLE METABOLOMIC SOFTWARE
    • TABLE 7: OPEN-ACCESS TOOLS FOR COMPLEX LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY DATA ANALYSIS
  • CHEMINFORMATIC ADVANCES
    • TABLE 8: CHEMINFORMATIC SOFTWARE SOLUTIONS FOR DRUG RESEARCH AND DEVELOPMENT
  • EMERGING TECHNOLOGIES
    • METAGENOMIC ADVANCES
      • TABLE 9: BIOINFORMATIC TOOLS FOR METAGENOMIC STUDIES
  • EPIGENOMIC ADVANCES
  • PHARMACOGENOMIC ADVANCES
    • PHARMACOGENOMICS AND PRECISION MEDICINE
    • VALUE-BASED DECISIONS
    • PHARMACOGENOMICS AND RESEARCH AND DEVELOPMENT
      • TABLE 10: BIOINFORMATIC TOOLS FOR PHARMACOGENOMIC STUDIES
    • INTERNATIONAL SERIOUS ADVERSE EVENTS CONSORTIUM
    • PHARMACOGENOMIC SOFTWARE
      • TABLE 11: BIOINFORMATIC TOOLS FOR PHARMACOGENOMIC SOFTWARE
  • TOXICOGENOMIC ADVANCES
    • TOXCAST COMPUTATIONAL TOXICOLOGY RESEARCH PROGRAM
    • CUSTOMIZED TOXICOGENOMIC PLATFORMS
  • DATABASE MANAGEMENT SERVICES
    • TABLE 12: ARCHIVAL DATABASES
    • TABLE 13: CURATIVE DATABASES
    • TABLE 14: COMMERCIALLY AVAILABLE DATABASES
  • MARKET DYNAMICS

CHAPTER 5 - BIOINFORMATICS: DATA ANALYSIS AND SOFTWARE

  • INTRODUCTION
  • DATA ANALYSIS SOFTWARE
    • FIGURE 7: EUROPEAN BIOINFORMATIC INSTITUTE SOFTWARE SOLUTIONS
    • TABLE 15: SOFTWARE FOR BIOLOGICAL ANALYSIS
    • TABLE 16: POPULAR COMMERCIALLY AVAILABLE BIOINFORMATIC PROGRAMS FOR NEXT-GENERATION SEQUENCING ANALYSIS
  • BIOSIMULATION MODELS
  • MARKET ANALYSIS

CHAPTER 6 - BIOINFORMATICS: DATA PROCESSING AND STORAGE

  • MIND THE GAP
    • FIGURE 8: EVOLUTION OF INFORMATION TECHNOLOGY INFRASTRUCTURE
  • INFORMATION TECHNOLOGY INFRASTRUCTURE
    • TABLE 17: TOP 20 HARDWARE COMPANIES, 2010 ($MM/%)
  • HIGH-PERFORMANCE COMPUTING
    • TABLE 18: TOP SUPERCOMPUTERS, AS OF 2015
  • HIGH-PERFORMANCE COMPUTER CLUSTERS
    • CLOUD COMPUTING
      • FIGURE 9: SCHEMATIC REPRESENTATION OF CLOUD COMPUTING SERVICES
    • DATA AS A SERVICE
    • INFRASTRUCTURE AS A SERVICE
    • PLATFORM AS A SERVICE
    • SOFTWARE AS A SERVICE
      • TABLE 19: SOFTWARE AS A SERVICE RESOURCE
    • SECURITY AS A SERVICE
    • CLOUD COMPUTING CHALLENGES
    • FUTURE OF CLOUD COMPUTING
  • MARKET ANALYSIS

CHAPTER 7 - BIOINFORMATIC APPLICATIONS IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT

  • INTRODUCTION
    • TABLE 20: LEADING BIOINFORMATICS DATABASES
  • DRUG DISCOVERY AND DEVELOPMENT PROCESS
    • FIGURE 10: PHASES IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS
  • PRECLINICAL RESEARCH: DRUG DISCOVERY PHASE
    • TARGET IDENTIFICATION
    • TARGET VALIDATION
      • Role of Bioinformatics in Target Identification and Validation
        • TABLE 21: LEADING DRUG TARGET DATABASES
    • LEAD IDENTIFICATION
    • COMPUTER-AIDED DRUG DESIGN
      • FIGURE 11: BIOINFORMATIC INTERDISCIPLINARY NATURE
      • TABLE 22: COMPUTER SIMULATION PLATFORMS
    • LEAD OPTIMIZATION
    • CLINICAL RESEARCH: DRUG DEVELOPMENT
    • PRECLINICAL EXPERIMENTS
    • LABORATORY INFORMATION MANAGEMENT SYSTEMS
      • TABLE 23: LEADING LABORATORY INFORMATION MANAGEMENT SYSTEM PROVIDERS
    • ELECTRONIC LABORATORY NOTEBOOKS
      • FIGURE 12: INFORMATION SYSTEMS WITHIN THE LABORATORY ARCHITECTURE
      • TABLE 24: ELECTRONIC NOTEBOOKS USED WITHIN THE RESEARCH AND DEVELOPMENT ENVIRONMENT
      • TABLE 25: ELECTRONIC LABORATORY NOTEBOOKS USED WITHIN SPECIFIC AREAS OF BIOLOGY
    • INVESTIGATIONAL NEW DRUG APPLICATION
    • CLINICAL TRIALS
    • BIOINFORMATICS IN CLINICAL TRIAL DESIGN AND DATA COLLATION
      • TABLE 26: LEADING ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION AND TOXICITY PREDICTION TOOLS
    • NEW DRUG APPLICATION
    • NEW DRUG APPLICATION APPROVAL
      • TABLE 27: DRUG DEVELOPMENT PROCESS OVERVIEW
    • POST-LAUNCH ONGOING STUDIES AND PHASE IV CLINICAL TRIALS
    • ELECTRONIC HEALTH RECORDS
      • TABLE 28: LEADING ELECTRONIC HEALTH RECORD PROVIDERS, 2013
    • MOBILE HEALTH TECHNOLOGIES
      • TABLE 29: MEDICAL APPLICATIONS FOR HEALTHCARE PROFESSIONALS
    • RECENT PHARMACEUTICAL AND BIOINFORMATIC ALLIANCES AND PARTNERSHIPS
      • TABLE 30: PHARMACEUTICAL AND BIOINFORMATIC PARTNERSHIPS AND ALLIANCES
    • CONCLUSIONS

CHAPTER 8 - MARKET TRENDS AND ANALYSIS

  • NORTH AMERICA
    • TABLE 31: NORTH AMERICAN BIOINFORMATIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • UNITED STATES
    • TABLE 32: LEADING BIOINFORMATIC COMPANIES IN THE U.S.
    • TABLE 33: TOP 15 VENTURE CAPITAL COMPANIES MOST ACTIVE IN THE LIFE SCIENCE SECTOR, THROUGH 2012
    • TABLE 34: U.S. BIOINFORMATIC MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: U.S. BIOINFORMATIC MARKET BY CATEGORY, THROUGH 2019 ($ MILLIONS)
  • CANADA
    • TABLE 36: CANADIAN BIOINFORMATIC MARKET BY CATEGORY, THROUGH 2019 ($ MILLIONS)
    • TABLE 37: LEADING CANADIAN BIOINFORMATIC COMPANIES
    • TABLE 38: CANADIAN BIOINFORMATIC MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
  • EUROPE
    • TABLE 39: EUROPEAN BIOINFORMATIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 40: LEADING EUROPEAN BIOINFORMATIC COMPANIES
  • U.K.
    • TABLE 41: U.K. BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 42: U.K. BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
  • GERMANY
    • TABLE 43: GERMAN BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 44: GERMAN BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
  • SWITZERLAND
    • TABLE 45: SWISS BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 46: SWISS BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
  • ASIA-PACIFIC
    • TABLE 47: ASIA-PACIFIC BIOINFORMATIC MARKET BY REGION,THROUGH 2019 ($ MILLIONS)
  • INDIA
    • TABLE 48: INDIAN BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • FIGURE 13: KEY AREAS OF RESEARCH UTILIZING BIOINFORMATICS
    • TABLE 49: LEADING INDIAN BIOINFORMATIC COMPANIES
    • TABLE 50: INDIAN BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
  • CHINA
    • TABLE 51: CHINESE BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 52: CHINESE BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
  • CONCLUSIONS

CHAPTER 9 - COMPANY PROFILES

  • 3RD MILLENNIUM INC.
  • ASTRID BIOSCIENCE GMBH
  • BIOBASE GMBH
  • BIOMATTERS LTD.
  • CLC BIOINFORMATICS
  • CONEXIO GENOMICS PRIVATE LTD.
  • COMPUGEN LTD.
  • DASSAULT SYSTEMES SA
  • DNASTAR INC.
  • GEOSPIZA INC.
  • GENOMATIX SOFTWARE GMBH
  • GVK BIOSCIENCES PRIVATE LTD.
  • GENOLOGICS LIFESCIENCES SOFTWARE INC.
  • GENEDATA AG
  • GENEVA BIOFORMATICS (GENEBIO) SA
  • GNS HEALTHCARE INC.
  • ILLUMINA INC.
  • MOLECULAR CONNECTIONS PRIVATE LTD.
  • MOLECULAR NETWORKS GMBH
  • NONLINEAR DYNAMICS LTD.
  • OCIMUM BIOSOLUTIONS LTD.
  • PERKIN ELMER INFORMATICS INC.
  • PERSONALIS INC.
  • SMARTGENE SERVICES SARL
  • REAL TIME GENOMICS INC.

CHAPTER 10 - APPENDIX ONE: ACRONYMS

CHAPTER 11 - REFERENCES

  • ENDNOTES

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL BIOINFORMATIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: U.S. FOOD AND DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVALS, 2009-2014
    • TABLE 2: GLOBAL BIOINFORMATIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 3: PUBLIC FUNDING PROGRAMS, 2005-2014
    • TABLE 4: GLOBAL BIOINFORMATIC MARKET BY CATEGORY, THROUGH 2019 ($ MILLIONS)
    • TABLE 5: GLOBAL BIOINFORMATIC MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 6: COMMERCIALLY AVAILABLE METABOLOMIC SOFTWARE
    • TABLE 7: OPEN-ACCESS TOOLS FOR COMPLEX LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY DATA ANALYSIS
    • TABLE 8: CHEMINFORMATIC SOFTWARE SOLUTIONS FOR DRUG RESEARCH AND DEVELOPMENT
    • TABLE 9: BIOINFORMATIC TOOLS FOR METAGENOMIC STUDIES
    • TABLE 10: BIOINFORMATIC TOOLS FOR PHARMACOGENOMIC STUDIES
    • TABLE 11: BIOINFORMATIC TOOLS FOR PHARMACOGENOMIC SOFTWARE
    • TABLE 12: ARCHIVAL DATABASES
    • TABLE 13: CURATIVE DATABASES
    • TABLE 14: COMMERCIALLY AVAILABLE DATABASES
    • TABLE 15: SOFTWARE FOR BIOLOGICAL ANALYSIS
    • TABLE 16: POPULAR COMMERCIALLY AVAILABLE BIOINFORMATIC PROGRAMS FOR NEXT-GENERATION SEQUENCING ANALYSIS
    • TABLE 17: TOP 20 HARDWARE COMPANIES, 2010 ($MM/%)
    • TABLE 18: TOP SUPERCOMPUTERS, AS OF 2015
    • TABLE 19: SOFTWARE AS A SERVICE RESOURCE
    • TABLE 20: LEADING BIOINFORMATICS DATABASES
    • TABLE 21: LEADING DRUG TARGET DATABASES
    • TABLE 22: COMPUTER SIMULATION PLATFORMS
    • TABLE 23: LEADING LABORATORY INFORMATION MANAGEMENT SYSTEM PROVIDERS
    • TABLE 24: ELECTRONIC NOTEBOOKS USED WITHIN THE RESEARCH AND DEVELOPMENT ENVIRONMENT
    • TABLE 25: ELECTRONIC LABORATORY NOTEBOOKS USED WITHIN SPECIFIC AREAS OF BIOLOGY
    • TABLE 26: LEADING ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION AND TOXICITY PREDICTION TOOLS
    • TABLE 27: DRUG DEVELOPMENT PROCESS OVERVIEW
    • TABLE 28: LEADING ELECTRONIC HEALTH RECORD PROVIDERS, 2013
    • TABLE 29: MEDICAL APPLICATIONS FOR HEALTHCARE PROFESSIONALS
    • TABLE 30: PHARMACEUTICAL AND BIOINFORMATIC PARTNERSHIPS AND ALLIANCES
    • TABLE 31: NORTH AMERICAN BIOINFORMATIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: LEADING BIOINFORMATIC COMPANIES IN THE U.S.
    • TABLE 33: TOP 15 VENTURE CAPITAL COMPANIES MOST ACTIVE IN THE LIFE SCIENCE SECTOR, THROUGH 2012
    • TABLE 34: U.S. BIOINFORMATIC MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: U.S. BIOINFORMATIC MARKET BY CATEGORY, THROUGH 2019 ($ MILLIONS)
    • TABLE 36: CANADIAN BIOINFORMATIC MARKET BY CATEGORY, THROUGH 2019 ($ MILLIONS)
    • TABLE 37: LEADING CANADIAN BIOINFORMATIC COMPANIES
    • TABLE 38: CANADIAN BIOINFORMATIC MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 39: EUROPEAN BIOINFORMATIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 40: LEADING EUROPEAN BIOINFORMATIC COMPANIES
    • TABLE 41: U.K. BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 42: U.K. BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
    • TABLE 43: GERMAN BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 44: GERMAN BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
    • TABLE 45: SWISS BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 46: SWISS BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
    • TABLE 47: ASIA-PACIFIC BIOINFORMATIC MARKET BY REGION,THROUGH 2019 ($ MILLIONS)
    • TABLE 48: INDIAN BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 49: LEADING INDIAN BIOINFORMATIC COMPANIES
    • TABLE 50: INDIAN BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)
    • TABLE 51: CHINESE BIOINFORMATIC MARKET BY CATEGORY,THROUGH 2019 ($ MILLIONS)
    • TABLE 52: CHINESE BIOINFORMATIC MARKET BY APPLICATION,THROUGH 2019 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL BIOINFORMATIC MARKET BY REGION, 2013-2019 ($ MILLIONS)
    • FIGURE 1: RELATIONSHIP OF BIOINFORMATICS WITH 'OMIC TECHNOLOGIES
    • FIGURE 2: SCHEMATIC REPRESENTATION OF BIOLOGY SYSTEMS AND TRANSLATIONAL BIOINFORMATICS
    • FIGURE 3: PRINCIPLES OF PRECISION MEDICINE
    • FIGURE 4: APPLICATIONS OF BIOINFORMATICS ON DRUG DEVELOPMENT
    • FIGURE 5: FOUR DIMENSIONS OF BIG DATA
    • FIGURE 6: TOP-DOWN PROTEOMIC APPROACH
    • FIGURE 7: EUROPEAN BIOINFORMATIC INSTITUTE SOFTWARE SOLUTIONS
    • FIGURE 8: EVOLUTION OF INFORMATION TECHNOLOGY INFRASTRUCTURE
    • FIGURE 9: SCHEMATIC REPRESENTATION OF CLOUD COMPUTING SERVICES
    • FIGURE 10: PHASES IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS
    • FIGURE 11: BIOINFORMATIC INTERDISCIPLINARY NATURE
    • FIGURE 12: INFORMATION SYSTEMS WITHIN THE LABORATORY ARCHITECTURE
    • FIGURE 13: KEY AREAS OF RESEARCH UTILIZING BIOINFORMATICS 128
Back to Top